{"warning_section":[],"available_generic":"","has_child_version":[],"synonyms":[],"overdose_section":[{"text":[{"text_type":"paragraph","value":"There is no information on overdosage with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in humans."},{"text_type":"paragraph","value":"\n\nOlmesartan medoxomil.\n Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurs.\u00a0 If symptomatic hypotension should occur, supportive treatment should be initiated.\u00a0 The dialyzability of olmesartan is unknown."},{"text_type":"paragraph","value":"\n\nAmlodipine.\n Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m2basis) caused a marked peripheral vasodilation and hypotension."},{"text_type":"paragraph","value":"Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia.\u00a0 In humans, experience with intentional overdosage of amlodipine is limited."},{"text_type":"paragraph","value":"If massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit."},{"text_type":"paragraph","value":"\n\nHydrochlorothiazide.\n The most common signs and symptoms of overdose observed in humans are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats, more than 1000-fold the highest recommended human dose."}],"title":"unable_to_match_title"}],"brand_names":[{"name":"Tribenzor","rxcui":"1372732"},""],"can_be_prescribed":{"US":"yes"},"available_strengths":["5 MG / 25 MG / 40 MG"],"similar_drugs":[],"drug_class_use":[],"contraindicated_conditions":{"Amlodipine":["Drug Hypersensitivity","Hypotension"],"Olmesartan":["Drug Hypersensitivity","Hypotension","Hyperaldosteronism","Pregnancy"],"Hydrochlorothiazide":["Drug Hypersensitivity","Pregnancy","Anuria","Kidney Failure"]},"storage_and_handling":[],"usage_instructions":[{"text":[{"text_type":"unordered_list","value":["Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are a combination of an angiotensin 2 receptor blocker, a dihydropyridine calcium channel blocker, and a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1)."]},{"text_type":"paragraph","value":"\u00a0 Limitations of Use\n"},{"text_type":"paragraph","value":"\u00a0Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets is not indicated for initial therapy."},{"text_type":"paragraph","value":"Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets."},{"text_type":"paragraph","value":"Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)."},{"text_type":"paragraph","value":"Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly."},{"text_type":"paragraph","value":"Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal."},{"text_type":"paragraph","value":"Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy."},{"text_type":"paragraph","value":"\nLimitations of Use \n"},{"text_type":"paragraph","value":"This fixed combination drug is not indicated for the initial therapy of hypertension."}],"title":"unable_to_match_title"}],"overdose_risk":"","name":"Amlodipine 5 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet","alcohol_interaction":[],"breastfeeding_interaction":[],"is_addictive":[],"concept_type":"clinical_drug","drug_class":[],"ndfrt_properties":{"ingredients":{"Olmesartan Medoxomil":["Olmesartan Medoxomil"],"Olmesartan":["Olmesartan"],"Amlodipine":["Amlodipine"],"Hydrochlorothiazide":["Hydrochlorothiazide"]},"methods_of_action_fdaspl":{"Amlodipine":["Calcium Channel Antagonists"],"Olmesartan":["Angiotensin 2 Receptor Antagonists"]},"physical_effects":{"Amlodipine":["Coronary Arterial Vasodilation","Arterial Vasodilation","Decreased Blood Pressure"],"Olmesartan":["Decreased Renal K+ Excretion","Arterial Vasodilation","Decreased Mineralocorticoid Secretion","Renal Arterial Vasodilation","Decreased Intravascular Volume","Decreased Blood Pressure","Increased Renal Na+ Excretion"],"Hydrochlorothiazide":["Decreased Distal Tubule Ca++ Excretion","Decreased Blood Pressure","Vasodilation","Increased Distal Tubule H+ Excretion","Decreased Intravascular Volume","Increased Distal Tubule Na+ Excretion","Increased Distal Tubule K+ Excretion","Increased Distal Tubule Cl- Excretion"]},"product_components":{"Amlodipine 5Mg/Hydrochlorothiazide 25Mg/Olmesartan 40Mg Tab":["Olmesartan Medoxomil","Hydrochlorothiazide","Amlodipine"]},"ci_chemical_class":{"Hydrochlorothiazide":["Sulfonamides"]},"physical_effects_fdaspl":{"Hydrochlorothiazide":["Increased Diuresis"]},"contraindicated_conditions":{"Amlodipine":["Drug Hypersensitivity","Hypotension"],"Olmesartan":["Drug Hypersensitivity","Hypotension","Hyperaldosteronism","Pregnancy"],"Hydrochlorothiazide":["Drug Hypersensitivity","Pregnancy","Anuria","Kidney Failure"]},"is_a":{"Amlodipine 5Mg/Hydrochlorothiazide 25Mg/Olmesartan 40Mg Tab":["Antihypertensive Combinations","Amlodipine/Hydrochlorothiazide/Olmesartan"],"Olmesartan Medoxomil":["Olmesartan"],"Olmesartan":["Angiotensin 2 Receptor Blocker","O [Preparations]"],"Hydrochlorothiazide":["H [Preparations]","Thiazide Diuretic"],"Amlodipine":["Dihydropyridine Calcium Channel Blocker","A [Preparations]"],"Amlodipine/Hydrochlorothiazide/Olmesartan":["A [Preparations]"]},"pharmacokinetics":{"Hydrochlorothiazide":["Renal Excretion"]},"methods_of_action":{"Amlodipine":["L-Calcium Channel Receptor Antagonists"],"Olmesartan":["Angiotensin 2 Receptor Antagonists"],"Hydrochlorothiazide":["Sodium Chloride Symporter Inhibitors"]},"chemical_structures_fdaspl":{"Amlodipine":["Dihydropyridines"],"Hydrochlorothiazide":["Thiazides"]},"may_treat":{"Amlodipine":["Coronary Artery Disease","Angina Pectoris","Angina Pectoris, Variant","Hypertension"],"Olmesartan":["Heart Failure","Ventricular Dysfunction, Left","Diabetic Nephropathies","Hypertension"],"Hydrochlorothiazide":["Hypertension","Heart Failure","Nephrotic Syndrome","Edema"]},"available_dose_forms":{"Amlodipine 5Mg/Hydrochlorothiazide 25Mg/Olmesartan 40Mg Tab":["Oral Tablet"]},"ci_physical_effects":{"Olmesartan":["Renal Arterial Vasoconstriction"]}},"dosage_instructions":[],"withdrawal_symptoms":[],"drug_forms":["Amlodipine / Hydrochlorothiazide / olmesartan Oral Tablet [Tribenzor]"],"side_effects":["dizziness","peripheral edema","headache","fatigue","nasopharyngitis","muscle spasms","nausea","upper respiratory tract infection","diarrhea","urinary tract infection","joint swelling"],"severe_drug_interactions":[],"pregnancy_category":{"US":"C"},"may_treat_conditions":{"Amlodipine":["Coronary Artery Disease","Angina Pectoris","Angina Pectoris, Variant","Hypertension"],"Olmesartan":["Heart Failure","Ventricular Dysfunction, Left","Diabetic Nephropathies","Hypertension"],"Hydrochlorothiazide":["Hypertension","Heart Failure","Nephrotic Syndrome","Edema"]},"may_treat_symptoms":["lightheadedness","vertigo","tinnitus"],"relations":{"clinical_drug_component":[{"name":"Hydrochlorothiazide 25 MG","rxcui":"316049"},{"name":"Amlodipine 5 MG","rxcui":"329528"},{"name":"Olmesartan medoxomil 40 MG","rxcui":"359114"}],"branded_dose_form":[{"name":"Amlodipine / Hydrochlorothiazide / olmesartan Oral Tablet [Tribenzor]","rxcui":"999970"}],"branded_drug_component":[{"name":"Amlodipine 5 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG [Tribenzor]","rxcui":"1000003"}],"brand_name":[{"name":"Tribenzor","rxcui":"1372732"}],"multiple_ingredients":[{"name":"Amlodipine / Hydrochlorothiazide / olmesartan","rxcui":"1008801"}],"ingredients":[{"name":"Amlodipine","rxcui":"17767"},{"name":"Hydrochlorothiazide","rxcui":"5487"},{"name":"olmesartan","rxcui":"321064"}],"branded_drug":[{"name":"Amlodipine 5 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet [Tribenzor]","rxcui":"1000005"}],"clinical_drug_dose_form":[{"name":"Amlodipine / Hydrochlorothiazide / olmesartan Oral Tablet","rxcui":"999966"}],"clinical_drug":[{"name":"Amlodipine 5 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet","rxcui":"1000001"}],"active_compound_group":{"name":"Amlodipine / Hydrochlorothiazide / olmesartan","rxcui":"1008801"}},"geriatric_use":[],"needs_prescription":{"US":"yes"},"overdose_seriousness":"","sections":{"adverse reactions":[{"text":[{"text_type":"paragraph","value":"Most common adverse reactions (incidence \u22652%) are dizziness, peripheral edema, headache, fatigue, nasopharyngitis, muscle spasms, nausea, upper respiratory tract infection, diarrhea, urinary tract infection, and joint swelling (6.1). "},{"text_type":"paragraph","value":"To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-269-544-2299 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice."},{"text_type":"paragraph","value":"\n\nOlmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets\n\n"},{"text_type":"paragraph","value":"In the controlled trial of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets,\u00a0 patients were randomized to olmesartan medoxomil, amlodipine and hydrochlorothiazide \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0tablets 40/10/25 mg, olmesartan medoxomil/amlodipine 40/10 mg, olmesartan medoxomil/hydrochlorothiazide 40/25 mg, or amlodipine/hydrochlorothiazide 10/25 mg. Subjects who received triple combination therapy were treated between two and four weeks with one of the three dual combination therapies. Safety data from this study were obtained in 574 patients with hypertension who received olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets for 8 weeks.\u00a0 "},{"text_type":"paragraph","value":"The frequency of adverse reactions was similar between men and women, patients <65 years of age and patients \u226565 years of age, patients with and without diabetes, and Black and non-Black patients.\u00a0 Discontinuations because of adverse events occurred in 4% of patients treated with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets 40/10/25 mg compared to 1% of\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 patients treated with olmesartan medoxomil/amlodipine 40/10 mg, 2% of patients treated with\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 olmesartan medoxomil/hydrochlorothiazide 40/25 mg, and 2% of patients treated with amlodipine/hydrochlorothiazide 10/25 mg. The most common reason for discontinuation with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets was dizziness (1%).\u00a0 "},{"text_type":"paragraph","value":"Dizziness was one of the most frequently reported adverse reactions with incidence of 1.4% to 3.6% in subjects continuing on dual combination therapy compared to 5.8% to 8.9% in subjects who switched to olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets."},{"text_type":"paragraph","value":"The other most frequent adverse reactions that occurred in at least 2% of subjects are presented in the table below:"},{"text_type":"paragraph","value":"Syncope was reported by 1% of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets subjects compared to 0.5% or less for the other treatment groups."},{"text_type":"paragraph","value":"\n\nOlmesartan medoxomil\n\n"},{"text_type":"paragraph","value":"Olmesartan medoxomil has been evaluated for safety in more than 3825 patients/subjects, including more than 3275 patients treated for hypertension in controlled trials. This experience included about 900 patients treated for at least 6 months and more than 525 treated for at least 1 year.\u00a0 Treatment with olmesartan medoxomil was well tolerated, with an incidence of adverse reactions similar to that seen with placebo. Adverse reactions were generally mild, transient, and without relationship to the dose of olmesartan medoxomil."},{"text_type":"paragraph","value":"\n\nAmlodipine\n\n"},{"text_type":"paragraph","value":"Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials."},{"text_type":"paragraph","value":"The following adverse reactions occurred in <1% but >0.1% of patients in controlled clinical trials under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert physicians to a possible relationship:"},{"text_type":"paragraph","value":"\nCardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, hypotension, peripheral ischemia, syncope, tachycardia, postural dizziness, postural hypotension, vasculitis"},{"text_type":"paragraph","value":"\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Central and Peripheral Nervous System: hypoesthesia, neuropathy peripheral, \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 paresthesia, tremor, vertigo"},{"text_type":"paragraph","value":"\nGastrointestinal: anorexia, constipation, dyspepsia*, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia"},{"text_type":"paragraph","value":"\nGeneral: allergic reaction, asthenia*, back pain, hot flushes, malaise, pain, rigors, weight gain, weight decrease"},{"text_type":"paragraph","value":"\nMusculoskeletal System: arthralgia, arthrosis, muscle cramps*, myalgia "},{"text_type":"paragraph","value":"\nPsychiatric: sexual dysfunction (male* and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization"},{"text_type":"paragraph","value":"\nRespiratory: dyspnea*, epistaxis"},{"text_type":"paragraph","value":"\nSkin and Appendages: angioedema, erythema multiforme, pruritus*, rash*, rash erythematous, rash maculopapular"},{"text_type":"paragraph","value":"\nSpecial Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus "},{"text_type":"paragraph","value":"\nUrinary System: micturition frequency, micturition disorder, nocturia"},{"text_type":"paragraph","value":"\nAutonomic Nervous System: dry mouth, sweating increased"},{"text_type":"paragraph","value":"\nMetabolic and Nutritional: hyperglycemia, thirst"},{"text_type":"paragraph","value":"\nHemopoietic: leukopenia, purpura, thrombocytopenia"},{"text_type":"paragraph","value":"\n* = events that occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies."},{"text_type":"paragraph","value":"The following adverse reactions occurred in <0.1% of patients: cardiac failure, pulse irregularity, extrasystoles, skin discoloration, urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia, hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, increased appetite, loose stools, coughing, rhinitis, dysuria, polyuria, parosmia, taste perversion, abnormal visual accommodation, and xerophthalmia."},{"text_type":"paragraph","value":"\n\nHydrochlorothiazide\n\n"},{"text_type":"paragraph","value":"Other adverse reactions that have been reported with hydrochlorothiazide, without regard to causality, are listed below:"},{"text_type":"paragraph","value":"\nBody as a Whole: weakness"},{"text_type":"paragraph","value":"\nDigestive: pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation"},{"text_type":"paragraph","value":"\nHematologic: aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia"},{"text_type":"paragraph","value":"\nHypersensitivity: purpura, photosensitivity, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions"},{"text_type":"paragraph","value":"\nMetabolic: hyperglycemia, glycosuria, hyperuricemia"},{"text_type":"paragraph","value":"\nMusculoskeletal: muscle spasm"},{"text_type":"paragraph","value":"\nNervous System/Psychiatric: restlessness"},{"text_type":"paragraph","value":"\nRenal: renal failure, renal dysfunction, interstitial nephritis"},{"text_type":"paragraph","value":"\nSkin: erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis"},{"text_type":"paragraph","value":"\nSpecial Senses: transient blurred vision, xanthopsia"}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"The following adverse reactions have been identified during post-approval use of the individual components of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets.\u00a0 Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure."},{"text_type":"paragraph","value":"\n\nOlmesartan medoxomil.\n The following adverse reactions have been reported in post-marketing experience:"},{"text_type":"paragraph","value":"\nBody as a Whole: asthenia, angioedema, anaphylactic reactions, peripheral edema"},{"text_type":"paragraph","value":"\nGastrointestinal: vomiting, diarrhea, sprue-like enteropathy [see Warnings and Precautions\n (5.10)]\n"},{"text_type":"paragraph","value":"\nMetabolic and Nutritional Disorders: hyperkalemia"},{"text_type":"paragraph","value":"\nMusculoskeletal: rhabdomyolysis"},{"text_type":"paragraph","value":"\nUrogenital System: acute renal failure"},{"text_type":"paragraph","value":"\nSkin and Appendages: alopecia, pruritus, urticaria"},{"text_type":"paragraph","value":"Data from one controlled trial and an epidemiologic study have suggested that high-dose olmesartan may increase cardiovascular (CV) risk in diabetic patients, but the overall data are not conclusive. The randomized, placebo-controlled, double-blind ROADMAP trial (Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention trial, n=4447) examined the use of olmesartan, 40 mg daily, vs. placebo in patients with type 2 diabetes mellitus, normoalbuminuria, and at least one additional risk factor for CV disease. The trial met its primary endpoint, delayed onset of microalbuminuria, but olmesartan had no beneficial effect on decline in glomerular filtration rate (GFR). There was a finding of increased CV mortality (adjudicated sudden cardiac death, fatal myocardial infarction, fatal stroke, revascularization death) in the olmesartan group compared to the placebo group (15 olmesartan vs. 3 placebo, HR 4.9, 95% confidence interval , 1.4, 17), but the risk of non-fatal myocardial infarction was lower with olmesartan (HR 0.64, 95% CI 0.35, 1.18). "},{"text_type":"paragraph","value":"The epidemiologic study included patients 65 years and older with overall exposure of > 300,000 patient-years. In the sub-group of diabetic patients receiving high-dose olmesartan (40 mg/d) for > 6 months, there appeared to be an increased risk of death (HR 2.0, 95% CI 1.1, 3.8) compared to similar patients taking other angiotensin receptor blockers. In contrast, high-dose olmesartan use in non-diabetic patients appeared to be associated with a decreased risk of death (HR 0.46, 95% CI 0.24, 0.86) compared to similar patients taking other angiotensin receptor blockers. No differences were observed between the groups receiving lower doses of olmesartan compared to other angiotensin blockers or those receiving therapy for < 6 months. "},{"text_type":"paragraph","value":"Overall, these data raise a concern of a possible increased CV risk associated with the use of high-dose olmesartan in diabetic patients. There are, however, concerns with the credibility of the finding of increased CV risk, notably the observation in the large epidemiologic study for a survival benefit in non-diabetics of a magnitude similar to the adverse finding in diabetics."},{"text_type":"paragraph","value":"\n\nAmlodipine.\n The following post-marketing event has been reported infrequently where a causal relationship is uncertain: gynecomastia.\u00a0 In post-marketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine."}],"title":"unable_to_match_title"}],"clinical pharmacology":[{"text":[],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"The active ingredients of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets target three separate mechanisms involved in blood pressure regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; olmesartan medoxomil blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells; and hydrochlorothiazide directly promotes the excretion of sodium and chloride in the kidney leading to reductions in intravascular volume.\u00a0 For a more detailed description of the mechanisms of action for each individual component, see below."},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. Angiotensin II is formed from angiotensin I in a reaction catalyzed by ACE, kininase II.\u00a0 Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.\u00a0 Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis."},{"text_type":"paragraph","value":"An AT2 receptor is found also in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis.\u00a0 Olmesartan has more than a 12,500-fold greater affinity for the AT1 receptor than for the AT2 receptor. "},{"text_type":"paragraph","value":"Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is a mechanism of many drugs used to treat hypertension. Angiotensin-converting enzyme inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE.\u00a0 Because olmesartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known."},{"text_type":"paragraph","value":"Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II levels do not overcome the effect of olmesartan on blood pressure."},{"text_type":"paragraph","value":"\nAmlodipine.\n Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggests that amlodipine binds to both dihydropyridine and nonhydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.\u00a0 Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells.\u00a0 Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine.\u00a0 Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect."},{"text_type":"paragraph","value":"Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure."},{"text_type":"paragraph","value":"\nHydrochlorothiazide.\n Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so co-administration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics."},{"text_type":"paragraph","value":"The mechanism of the antihypertensive effect of thiazides is not fully understood."}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets have been shown to be effective in lowering blood pressure. The three components of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets lower the blood pressure through complementary mechanisms, each working at a separate site and blocking different effects or pathways. The pharmacodynamics of each individual component is described below."},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. Olmesartan medoxomil doses of 2.5 to 40 mg inhibit the pressor effects of angiotensin I infusion. The duration of the inhibitory effect was related to dose, with doses of olmesartan medoxomil >40 mg giving >90% inhibition at 24 hours."},{"text_type":"paragraph","value":"Plasma concentrations of angiotensin I and angiotensin II and plasma renin activity (PRA) increase after single and repeated administration of olmesartan medoxomil to healthy subjects and hypertensive patients. Repeated administration of up to 80 mg olmesartan medoxomil had minimal influence on aldosterone levels and no effect on serum potassium.\u00a0 "},{"text_type":"paragraph","value":"\nAmlodipine. Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.\u00a0 "},{"text_type":"paragraph","value":"With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 105 to 114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90 to 104 mmHg). Normotensive patients experienced no clinically significant change in blood pressures (+1/-2 mmHg)."},{"text_type":"paragraph","value":"In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria."},{"text_type":"paragraph","value":"As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume.\u00a0 In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man. Similar findings, however, have been observed in normal or well-compensated patients with heart failure with agents possessing significant negative inotropic effects."},{"text_type":"paragraph","value":"Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed."},{"text_type":"paragraph","value":"\nHydrochlorothiazide. After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours, and lasts about 6 to 12 hours."},{"text_type":"paragraph","value":"Drug Interactions"},{"text_type":"paragraph","value":"\nAlcohol, Barbiturates, or Narcotics: Potentiation of orthostatic hypotension may occur."},{"text_type":"paragraph","value":"\nSkeletal muscle relaxants, non-depolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant."}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"\nOlmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets. After oral administration of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in normal healthy adults, peak plasma concentrations of olmesartan, amlodipine, and hydrochlorothiazide are reached in about 1.5 to 3 hours, 6 to 8 hours, and 1.5 to 2 hours, respectively. The rate and extent of absorption of olmesartan medoxomil, amlodipine, and hydrochlorothiazide from olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are the same as when administered as individual dosage forms. Food does not affect the bioavailability of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets."},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. Olmesartan medoxomil is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. The absolute bioavailability of olmesartan medoxomil is approximately 26%.\u00a0 After oral administration, the Cmax of olmesartan is reached after 1 to 2 hours.\u00a0 Food does not affect the bioavailability of olmesartan medoxomil."},{"text_type":"paragraph","value":"\nAmlodipine. After oral administration of therapeutic doses of amlodipine, absorption produces peak plasma concentrations between 6 and 12 hours.\u00a0 Absolute bioavailability is estimated between 64% and 90%.\u00a0 "},{"text_type":"paragraph","value":"\nHydrochlorothiazide. When plasma levels have been followed for at least 24 hours, the plasma\u00a0\u00a0 half-life has been observed to vary between 5.6 and 14.8 hours."},{"text_type":"paragraph","value":"\nDistribution\n"},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. The volume of distribution of olmesartan is approximately 17 L. Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells. The protein binding is constant at plasma olmesartan concentrations well above the range achieved with recommended doses."},{"text_type":"paragraph","value":"In rats, olmesartan crossed the blood-brain barrier poorly, if at all. Olmesartan passed across the placental barrier in rats and was distributed to the fetus. Olmesartan was distributed to milk at low levels in rats."},{"text_type":"paragraph","value":"\nAmlodipine.\u00a0Ex vivo studies have shown that approximately 93% of the circulating drug is bound to plasma proteins in hypertensive patients.\u00a0 Steady-state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing."},{"text_type":"paragraph","value":"\nHydrochlorothiazide. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk."},{"text_type":"paragraph","value":"\nMetabolism and Excretion\n"},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. Following the rapid and complete conversion of olmesartan medoxomil to olmesartan during absorption, there is virtually no further metabolism of olmesartan. Total plasma clearance of olmesartan is 1.3 L/h, with a renal clearance of 0.6 L/h. Approximately 35% to 50% of the absorbed dose is recovered in urine while the remainder is eliminated in feces via the bile.\u00a0 "},{"text_type":"paragraph","value":"Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours. Olmesartan shows linear pharmacokinetics following single oral doses of up to 320 mg and multiple oral doses of up to 80 mg. Steady-state levels of olmesartan are achieved within 3 to 5 days and no accumulation in plasma occurs with once-daily dosing."},{"text_type":"paragraph","value":"\nAmlodipine. Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism. Elimination from the plasma is biphasic with a terminal elimination half-life of about 30 to 50 hours. Ten percent of the parent compound and 60% of the metabolites are excreted in the urine."},{"text_type":"paragraph","value":"\nHydrochlorothiazide. Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.\u00a0 At least 61% of the oral dose is eliminated unchanged within 24 hours."},{"text_type":"paragraph","value":"\nSpecific Populations\n"},{"text_type":"paragraph","value":"\nGeriatric\n"},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. The pharmacokinetics of olmesartan medoxomil were studied in the elderly (\u226565 years). Overall, maximum plasma concentrations of olmesartan were similar in young adults and the elderly. Modest accumulation of olmesartan was observed in the elderly with repeated dosing; AUCss,\u03c4 was 33% higher in elderly patients, corresponding to an approximate 30% reduction in CLR."},{"text_type":"paragraph","value":"\nAmlodipine. Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40% to 60%, and a lower initial dose may be required."},{"text_type":"paragraph","value":"\n\nGender\n\n"},{"text_type":"paragraph","value":"Population pharmacokinetic analysis indicated that gender had no effect on the clearance of olmesartan and amlodipine. Female patients had approximately 20% smaller clearances of hydrochlorothiazide than male patients."},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. Minor differences were observed in the pharmacokinetics of olmesartan medoxomil in women compared to men. Area under the curve and Cmax were 10% to 15% higher in women than in men."},{"text_type":"paragraph","value":"\nRenal Insufficiency\n"},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. In patients with renal insufficiency, serum concentrations of olmesartan were elevated compared to subjects with normal renal function. After repeated dosing, the AUC was approximately tripled in patients with severe renal impairment (creatinine clearance <20 mL/min). The pharmacokinetics of olmesartan medoxomil in patients undergoing hemodialysis has not been studied."},{"text_type":"paragraph","value":"\nAmlodipine. The pharmacokinetics of amlodipine are not significantly influenced by renal impairment."},{"text_type":"paragraph","value":"\nHepatic Insufficiency\n"},{"text_type":"paragraph","value":"\nOlmesartan medoxomil. Increases in AUC0-\u221e and Cmax were observed in patients with moderate hepatic impairment compared to those in matched controls, with an increase in AUC of about 60%."},{"text_type":"paragraph","value":"\nAmlodipine. Patients with hepatic insufficiency have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40% to 60%."},{"text_type":"paragraph","value":"Heart Failure"},{"text_type":"paragraph","value":"\nAmlodipine. Patients with heart failure have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40% to 60%."},{"text_type":"paragraph","value":"\nDrug Interactions \n"},{"text_type":"paragraph","value":"\nSimvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. [see Drug Interactions (7.2)]. "},{"text_type":"paragraph","value":"\nCYP3A inhibitors: Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure. However, strong inhibitors of CYP3A (e.g., itraconazole, clarithromycin) may increase the plasma concentrations of amlodipine to a greater extent [see Drug Interactions (7.2)]. "},{"text_type":"paragraph","value":"\nCyclosporine: In a prospective study in renal transplant patients, an average 40% increase in trough cyclosporine levels was observed in the presence of amlodipine. [see Drug Interactions (7.2)]. "},{"text_type":"paragraph","value":"\nColesevelam: Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride in healthy subjects resulted in 28% reduction in Cmax and 39% reduction in AUC of olmesartan. Lesser effects, 4% and 15% reduction in Cmax and AUC respectively, were observed when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride [see Drug Interactions (7.1)]. "},{"text_type":"paragraph","value":"\nCimetidine: Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine. "},{"text_type":"paragraph","value":"\nGrapefruit juice: Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine. "},{"text_type":"paragraph","value":"\nMaalox\n\n\u00ae\n\n(antacid): Co-administration of the antacid Maalox\n\u00ae\nwith a single dose of amlodipine had no significant effect on the pharmacokinetics of amlodipine. "},{"text_type":"paragraph","value":"\nSildenafil: A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect. "},{"text_type":"paragraph","value":"\nAtorvastatin: Co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atorvastatin."},{"text_type":"paragraph","value":"\nDigoxin: Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers. "},{"text_type":"paragraph","value":"\nEthanol (alcohol): Single and multiple 10 mg doses of amlodipine had no significant effect on the pharmacokinetics of ethanol. "},{"text_type":"paragraph","value":"\nWarfarin: Co-administration of amlodipine with warfarin did not change the warfarin prothrombin response time. No significant drug interactions were reported in studies in which olmesartan medoxomil was coadministered with warfarin in healthy volunteers. "},{"text_type":"paragraph","value":"\nDigoxin: No significant drug interactions were reported in studies in which olmesartan medoxomil was coadministered with digoxin in healthy volunteers"},{"text_type":"paragraph","value":"\nAntacids: The bioavailability of olmesartan medoxomil was not significantly altered by the co-administration of antacids [Al(OH)3/Mg(OH)2]."}],"title":"unable_to_match_title"}],"description":[{"text":[{"text_type":"paragraph","value":"Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets provided as a tablet for oral administration, are a fixed combination of olmesartan medoxomil (ARB), amlodipine (CCB), and hydrochlorothiazide (thiazide diuretic)."},{"text_type":"paragraph","value":"Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract."},{"text_type":"paragraph","value":"The olmesartan medoxomil component of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets is chemically described as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1- methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate.\u00a0 Its empirical formula is C29H30N6O6."},{"text_type":"paragraph","value":"The amlodipine besylate component of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets is chemically described as 3-ethyl-5-methyl (\u00b1)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridinedicarboxylate, monobenzenesulphonate. Its empirical formula is C20H25CIN2O5\u2022C6H6O3S."},{"text_type":"paragraph","value":"The hydrochlorothiazide component of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets is chemically described as 6-chloro-3,4-dihydro-2H-1,2,4-benzo-thiazidiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8CIN3O4S2."},{"text_type":"paragraph","value":"The structural formula for olmesartan medoxomil, USP is:"},{"text_type":"paragraph","value":"The structural formula for amlodipine besylate, USP is:"},{"text_type":"paragraph","value":"The structural formula for hydrochlorothiazide, USP is: "},{"text_type":"paragraph","value":"Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets contain olmesartan medoxomil, USP a white to light yellowish-white powder or crystalline powder, amlodipine besylate, USP a white to off-white crystalline powder, and hydrochlorothiazide, USP a white or practically white, crystalline powder. The molecular weights of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide are 558.6, 567.1, and 297.7, respectively. Olmesartan medoxomil is practically insoluble in water and sparingly soluble in methanol. Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol. Hydrochlorothiazide is slightly soluble in water but freely soluble in sodium hydroxide solution."},{"text_type":"paragraph","value":"Each tablet of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets also contains the following inactive ingredients: colloidal silicone dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, maize starch, pregelatinized maize starch, silicified microcrystalline cellulose, and talc. The color coating contains opadry II pink (20/5/12.5 mg, 40/10/12.5 mg and 40/10/25 mg tablets), and opadry II yellow (40/5/12.5 mg and 40/5/25 mg tablets). "},{"text_type":"paragraph","value":"The color coating material contains the following ingredients."}],"title":"unable_to_match_title"}],"contraindications":[{"text":[{"text_type":"unordered_list","value":["Anuria: Hypersensitivity to sulfonamide-derived drugs (4).","Do not co-administer aliskiren with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in patients with diabetes (4)."]},{"text_type":"paragraph","value":"Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs."},{"text_type":"paragraph","value":"Do not co-administer aliskiren with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in patients with diabetes [See Drug Interactions (7.2)].\n"}],"title":"unable_to_match_title"}],"use in specific populations":[{"text":[{"text_type":"unordered_list","value":["Nursing mothers: Avoid use (8.3).","Renal Impairment: Avoid use in patients with creatinine clearance \u226430 mL/min (8.7)"]}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"Pregnancy Category D"},{"text_type":"paragraph","value":"Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus."},{"text_type":"paragraph","value":"In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets for hypotension, oliguria, and hyperkalemia [see Use in Specific Populations (8.4)].\n"}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"It is not known whether amlodipine or olmesartan are excreted in human milk, but thiazides appear in human milk and olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother."}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"Neonates with a history of in utero exposure to olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets:\u00a0 "},{"text_type":"paragraph","value":"If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function."},{"text_type":"paragraph","value":"The safety and effectiveness of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in pediatric patients have not been established."}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"\n\nOlmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets.\n In a controlled clinical trial, 123 hypertensive patients treated with Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets were \u226565 years of age and 18 patients were \u226575 years of age. No overall differences in the efficacy or safety of Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets were observed in these patient populations; however, greater sensitivity of some older individuals cannot be ruled out. The recommended initial dose of amlodipine in patients \u2265 75 years of age is 2.5 mg, a dose not available with Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets\n.\n\n"}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"There are no studies of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets in patients with hepatic insufficiency, but both amlodipine and olmesartan medoxomil show moderate increases in exposure in patients with severe hepatic impairment. The recommended initial dose of amlodipine in patients with severe hepatic impairment is 2.5 mg, a dose not available with Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets [see Warnings and Precautions (5.5)].\n"},{"text_type":"paragraph","value":"\n\u00a0Amlodipine. \nAmlodipine is extensively metabolized by the liver and the plasma elimination half-life (t\u00bd) is 56 hours in patients with severely impaired hepatic function. "},{"text_type":"paragraph","value":"\n\nOlmesartan medoxomil. \nIncreases in AUC0-\u221e and peak plasma concentration (Cmax) for olmesartan were observed with moderate hepatic impairment compared to those in matched controls with an increase in AUC of about 60%. "},{"text_type":"paragraph","value":"\n\nHydrochlorothiazide. \nIn patients with impaired hepatic function or progressive liver disease, minor alterations of fluid and electrolyte balance may precipitate hepatic coma."}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"There are no studies of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in patients with renal impairment. Avoid use in patients with severe renal impairment (creatinine clearance <30 mL/min).\u00a0 "},{"text_type":"paragraph","value":"\n\nOlmesartan medoxomil.\n Patients with renal insufficiency have elevated serum concentrations of olmesartan compared with patients with normal renal function. After repeated dosing, AUC was approximately tripled in patients with severe renal impairment (creatinine clearance <20 mL/min).\u00a0 No initial dosage adjustment is recommended for patients with moderate to marked renal impairment (creatinine clearance <40 mL/min). The pharmacokinetics of olmesartan in patients undergoing hemodialysis has not been studied."},{"text_type":"paragraph","value":"\n\nAmlodipine.\n The pharmacokinetics of amlodipine are not significantly influenced by renal impairment."},{"text_type":"paragraph","value":"\n\nHydrochlorothiazide.\n Thiazide should be used with caution in patients with severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function."}],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"Of the total number of patients who received olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in a randomized trial, 29% (184/627) were black. Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets were effective in lowering both systolic and diastolic blood pressure in black patients (usually a low-renin population) to the same extent as in non-black patients."}],"title":"unable_to_match_title"}],"indications and usage":[{"text":[{"text_type":"unordered_list","value":["Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are a combination of an angiotensin 2 receptor blocker, a dihydropyridine calcium channel blocker, and a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1)."]},{"text_type":"paragraph","value":"\u00a0 Limitations of Use\n"},{"text_type":"paragraph","value":"\u00a0Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets is not indicated for initial therapy."},{"text_type":"paragraph","value":"Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets."},{"text_type":"paragraph","value":"Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)."},{"text_type":"paragraph","value":"Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly."},{"text_type":"paragraph","value":"Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal."},{"text_type":"paragraph","value":"Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy."},{"text_type":"paragraph","value":"\nLimitations of Use \n"},{"text_type":"paragraph","value":"This fixed combination drug is not indicated for the initial therapy of hypertension."}],"title":"unable_to_match_title"}],"clinical studies":[{"text":[],"title":"unable_to_match_title"},{"text":[{"text_type":"paragraph","value":"The antihypertensive efficacy of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets was studied in a double-blind, active-controlled study in hypertensive patients. A total of 2492 patients with hypertension (mean baseline blood pressure 169/101 mmHg) received\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg (627 patients), olmesartan medoxomil/amlodipine 40/10 mg (628 patients), olmesartan medoxomil/hydrochlorothiazide\u00a0\u00a0\u00a0\u00a0\u00a0 40/25 mg (637 patients), or amlodipine/hydrochlorothiazide 10/25 mg (600 patients). Each subject was randomized to one of the three dual therapy combinations for two to four weeks. Patients were then randomized to continue on the dual therapy they were receiving or to receive triple therapy. A total of 53% of patients were male, 19% were 65 years or older, 67% were white, 30% were black, and 15% were diabetic."},{"text_type":"paragraph","value":"After 8 weeks of treatment, the triple combination therapy produced greater reductions in both systolic and diastolic blood pressures (p<0.0001) compared to each of the 3 dual combination therapies."},{"text_type":"paragraph","value":"The seated blood pressure reductions attributable to the addition of a single high-dose drug to each high-dose dual drug combination are shown in Table 2."},{"text_type":"paragraph","value":"There were no apparent differences in terms of seated diastolic blood pressure (SeDBP) or seated systolic blood pressure (SeSBP) reductions in black and non-black patients treated with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets [see Use in Specific Populations (8.8)]."},{"text_type":"paragraph","value":"There were no apparent differences in terms of SeDBP or SeSBP reductions in diabetic and\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 non-diabetic patients treated with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets."},{"text_type":"paragraph","value":"A total of 440 patients participated in the ambulatory blood pressure monitoring portion of the study. Over the 24-hour period, there was a greater reduction in diastolic and systolic ambulatory blood pressure for olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg compared to each of the dual combination therapies (see Figure 1 and Figure 2)."},{"text_type":"paragraph","value":"The blood pressure lowering effects of lower dose strengths of\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg, 40/5/12.5 mg, 40/10/12.5 mg, and 40/5/25 mg) have not been studied."},{"text_type":"paragraph","value":"All of the dose strengths of the triple combination are expected to provide superior blood pressure lowering effects compared to their respective mono and dual combination components.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The order of the blood pressure lowering effects among the different dose strengths\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets (olmesartan medoxomil / amlodipine/hydrochlorothiazide) is expected to be 20/5/12.5 mg < 40/5/12.5 mg < (40/10/12.5 mg \u2248 40/5/25 mg) < 40/10/25 mg."},{"text_type":"paragraph","value":"There are no trials of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets demonstrating reductions in cardiovascular risk in patients with hypertension, but at least one pharmacologically similar drug has demonstrated such benefits."}],"title":"unable_to_match_title"}],"overdosage":[{"text":[{"text_type":"paragraph","value":"There is no information on overdosage with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in humans."},{"text_type":"paragraph","value":"\n\nOlmesartan medoxomil.\n Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurs.\u00a0 If symptomatic hypotension should occur, supportive treatment should be initiated.\u00a0 The dialyzability of olmesartan is unknown."},{"text_type":"paragraph","value":"\n\nAmlodipine.\n Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m2basis) caused a marked peripheral vasodilation and hypotension."},{"text_type":"paragraph","value":"Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia.\u00a0 In humans, experience with intentional overdosage of amlodipine is limited."},{"text_type":"paragraph","value":"If massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit."},{"text_type":"paragraph","value":"\n\nHydrochlorothiazide.\n The most common signs and symptoms of overdose observed in humans are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats, more than 1000-fold the highest recommended human dose."}],"title":"unable_to_match_title"}]},"rxnorm_properties":{"prescribable":"Y","available_strength":"5 MG / 25 MG / 40 MG","human_drug":"US","general_cardinality":"MULTI","schedule":"0","tty":"SCD"},"rxcui":"1000001"}
